Baxter International Inc (BAX) concluded trading on Wednesday at a closing price of $29.60, with 4.59 million shares of worth about $135.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.70% during that period and on April 23, 2025 the price saw a gain of about 3.42%. Currently the company’s common shares owned by public are about 510.93M shares, out of which, 508.69M shares are available for trading.
Stock saw a price change of 6.47% in past 5 days and over the past one month there was a price change of -11.90%. Year-to-date (YTD), BAX shares are showing a performance of 1.51% which decreased to -25.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $26.25 but also hit the highest price of $41.18 during that period. The average intraday trading volume for Baxter International Inc shares is 4.95 million. The stock is currently trading -2.28% below its 20-day simple moving average (SMA20), while that difference is down -8.80% for SMA50 and it goes to -13.00% lower than SMA200.
Baxter International Inc (NYSE: BAX) currently have 510.93M outstanding shares and institutions hold larger chunk of about 95.64% of that.
The stock has a current market capitalization of $15.18B and its 3Y-monthly beta is at 0.67. It has posted earnings per share of -$1.27 in the same period. It has Quick Ratio of 1.05 while making debt-to-equity ratio of 1.93. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BAX, volatility over the week remained 3.19% while standing at 4.76% over the month.
Stock’s fiscal year EPS is expected to rise by 31.72% while it is estimated to increase by 9.63% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on February 26, 2025 offering a Buy rating for the stock and assigned a target price of $42 to it. On February 20, 2025, Barclays Resumed their recommendations, while on July 15, 2024, Morgan Stanley Downgrade their ratings for the stock with a price target of $30. Stock get a Neutral rating from Goldman on May 30, 2024.
